AstraZeneca plc with EPIC/TICKER LON:AZN has had its stock rating noted as ‘Reiteration’ with the recommendation being set at ‘BUY’ this morning by analysts at Liberum Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set a target price of 9430 GBX on its stock. This would imply the analyst believes there is now a potential upside of 26.3% from today’s opening price of 7465 GBX. Over the last 30 and 90 trading days the company share price has decreased 535 points and decreased 1241 points respectively.
AstraZeneca plc LON:AZN has a 50 day moving average of 8,191.58 GBX and a 200 Day Moving Average share price is recorded at 8,366.16The 52 week high for the share price is currently at 10120 GBX while the 52 week low for the stock is 5871 GBX. There are currently 1,312,660,216 shares in issue with the average daily volume traded being 3,291,940. Market capitalisation for LON:AZN is £98,733,577,665 GBP.
AstraZeneca plc 26.3% Potential Upside Indicated by Liberum Capital
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Charlotte Edwards
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
